CODX Stock Nearly Doubled In Early Trade – Co-Diagnostics’ Ebola Strategy Gets Retail Betting Big

• Co-Diagnostics develops molecular diagnostic tests using its proprietary Polymerase Chain Reaction technology platform.
• According to a Reuters report, the recent Ebola outbreak has already resulted in 131 deaths in the Democratic Republic of Congo, while health authorities have reported 516 suspected cases and 33 confirmed infections.
• On Tuesday, CODX stock recorded its biggest single-day gains in more than two months.

Shares of Co-Diagnostics (CODX) surged 93% on Tuesday, clocking their biggest single-day gains in more than two months, after the molecular diagnostics company announced it has completed the assay development strategy for the Bundibugyo virus, the strain linked to the ongoing Ebola outbreak in the Democratic Republic of Congo and Uganda.

The company develops molecular diagnostic tests using its proprietary Polymerase Chain Reaction (PCR) technology platform.

“We designed the Co-Dx PCR platform with these types of needs in mind, including the ability to support decentralized testing and cloud-connected architecture. Real-time visibility into outbreak activity can play an important role in helping public health authorities identify, monitor, and respond to emerging infectious disease threats,” said Dwight Egan, Co-Diagnostics’ CEO.

WHO Expresses Serious Concerns

The update comes as global health authorities ramp up monitoring efforts following recent Ebola cases in the region. The Centers for Disease Control and Prevention recently issued guidance calling for enhanced screening and monitoring of travelers arriving from outbreak-affected areas, including increased contact tracing and hospital preparedness measures.

On Tuesday, World Health Organization Director-General Tedros Adhanom Ghebreyesus voiced serious concern over the rapidly worsening Ebola outbreak, warning that both the scale and pace of infections are escalating.

According to a Reuters report, the outbreak has already resulted in 131 deaths in the Democratic Republic of Congo (DRC), while health authorities have reported 516 suspected cases and 33 confirmed infections. Uganda has also recorded two confirmed cases, raising fears that the disease could spread across borders.

Retail Bulls Bet Big On CODX

Retail sentiment for CODX on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, while message volumes on the platform were ‘high.’

One user said FDA clearance is imminent.

Another user expects the stock to rise to as high as $100.

Co-Diagnostics had implemented a 1-for-30 reverse stock split on Jan. 2, 2026.

Read also: Is ZETA Stock Mispriced? This Analyst Sees ‘Durable Advantages’ In ‘High-Growth, Cash-Generating’ Platform

For updates and corrections, email newsroom[at]stocktwits[dot]com.